{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-023788","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.248225+00:00","generated_at":"2026-05-22T03:48:05.484698+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Whitehawk Q1 net income $73M on divestiture gain; cash $231M, expects $185M into 2028","bullets":["Q1 2025 net income of $73.0M includes $87.4M gain from Aadi Sub divestiture; ex-gain net loss $14.4M.","Revenue $7.1M from FYARRO sales through March 25, 2025, date of divestiture to Kaken for $102.4M.","Cash and equivalents $231.1M at March 31, 2025 (vs $47.2M Dec 31, 2024) after closing $100M PIPE.","Expects cash of ~$185M after transaction payments, funding operations into 2028.","Oncology ADC pipeline: three assets targeting PTK7, MUC16, SEZ6; first IND on track for Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-023788","json":"https://secwatch.observer/filing/0001628280-25-023788.json","markdown":"https://secwatch.observer/filing/0001628280-25-023788.md","text":"https://secwatch.observer/filing/0001628280-25-023788.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000162828025023788/0001628280-25-023788-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000162828025023788/aadi-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:48:05.484698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}